Temodar showed some activity against ovarian cancer cell lines. A recent study looked at activity of Temodar in recurrent ovarian cancer (fallopian tumbe cancer is a type of oarian cancer). It enrolled fifteen patients and the median number of prior treatment regimens was 3. Hematologic toxicity was encountered in 26% of patients and was manageable. There were no complete or partial responses. One patient had stable disease with significant improvement in her performance status while on treatment. This study by Judson et al concluded that this dose and schedule of Temozolomide had insignificant activity in this heavily pretreated group of patients with persistent or recurrent ovarian or primary peritoneal carcinoma. Relapsed fallopian tube and ovarian cancer patients are eligible for a current study: A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients, NCT00526617. This Phase I clinical trial is studying the side effects and best dose of ABT-888 when given together with Temozolomide (chemotherapy) in treating patients with solid tumors, including metastatic melanoma (MM), BRCA deficient breast, ovarian, primary peritoneal, or fallopian tube cancer, and hepatocellular carcinoma (HCC). It is now in its phase II extension phase.
Carter, C.A., W.R. Waud, and J. Plowman. Responses of human melanoma, ovarian, and colon tumour xenografts in nude mice to oral temozolomide. Proc.Amer.Assoc.Cancer Res. 35: 297-(Abstract 1769)1994.
Patricia L. Judson, , C. Blair Harkness, Matthew P. Boente, Levi S. Downs, Jr. , Peter A. Argenta and Linda F. A phase II evaluation of Temozolomide in patients with recurrent epithelial ovarian cancer Gynecologic Oncology
Volume 93, Issue 3, June 2004, Pages 667-670